{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:19:52Z","timestamp":1783592392500,"version":"3.55.0"},"reference-count":40,"publisher":"Bioscientifica","issue":"2","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Liquid biopsies are a minimally invasive approach to obtain biomarkers including cell-free DNA (cfDNA) from peripheral blood. To date, there are limited and conflicting studies evaluating their role in thyroid cancer. Our study evaluated the utility of cfDNA in advanced thyroid cancers. Patients aged &amp;gt;18 years with metastatic medullary thyroid cancer (MTC), poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC) were enrolled in this prospective study between 2020 and 2024. As part of standard care, sequencing of germline and tumoral DNA was conducted, and patients with germline mutations were excluded from the study. Whole blood samples were collected in Streck cell-free DNA BCT tubes, and cfDNA was extracted from plasma using an EZ1&amp;2 ccfDNA kit and EZ2 Connect. The extracted cfDNA was then sequenced across 50 key cancer-related genes using an Oncomine Precision Assay panel on an Ion Torrent Genexus integrated sequencer. Forty patients were included: 27 MTC, 2 ATC and 11 PDTC. Tumoral mutations were detected in 36 of the included patients (90%): cfDNA detected mutations in 18\/36 patients (13 MTC, 1 ATC and 4 PDTC (50%)). The sensitivity of cfDNA was 86% (6\/7) pre-tyrosine kinase inhibitor therapy and reduced to 54% on therapy (13\/24), suggestive of the lack of tumor-derived DNA shedding with a strong on-target treatment efficacy. The median cfDNA concentration was higher in samples with a detected mutation (n = 43) than those without (n = 26), 11.91 ng\/mL vs 5.81 ng\/mL, respectively, while an increasing cfDNA was associated with worse progression-free survival (P &amp;lt; 0.01). cfDNA is a novel biomarker with potential to monitor disease progression in patients with advanced thyroid cancers.<\/jats:p>","DOI":"10.1530\/erc-24-0227","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:59:07Z","timestamp":1732712347000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the prognostic potential of circulating cell-free DNA in advanced thyroid cancer"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7868-7446","authenticated-orcid":true,"given":"Ayanthi","family":"Wijewardene","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Royal North Shore Hospital 1 , ,","place":["Sydney, Australia"]},{"name":"Cancer Genetics Laboratory, Kolling Institute, The University of Sydney 2 , ,","place":["Sydney, Australia"]},{"name":"Northern Clinical School, Faculty of Medicine and Health, The University of Sydney 3 , ,","place":["Sydney, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1545-0368","authenticated-orcid":true,"given":"Roderick J","family":"Clifton-Bligh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Royal North Shore Hospital 1 , ,","place":["Sydney, Australia"]},{"name":"Cancer Genetics Laboratory, Kolling Institute, The University of Sydney 2 , ,","place":["Sydney, Australia"]},{"name":"Northern Clinical School, Faculty of Medicine and Health, The University of Sydney 3 , ,","place":["Sydney, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Precision Medicine, SydPath, St Vincent\u2019s Hospital 4 , ,","place":["Sydney, Australia"]},{"name":"St Vincent\u2019s Clinical School, University of New South Wales 5 , ,","place":["New South Wales, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Luxford","sequence":"additional","affiliation":[{"name":"Cancer Genetics Laboratory, Kolling Institute, The University of Sydney 2 , ,","place":["Sydney, Australia"]},{"name":"Northern Clinical School, Faculty of Medicine and Health, The University of Sydney 3 , ,","place":["Sydney, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Royal North Shore Hospital 1 , ,","place":["Sydney, Australia"]},{"name":"Cancer Genetics Laboratory, Kolling Institute, The University of Sydney 2 , ,","place":["Sydney, Australia"]},{"name":"Northern Clinical School, Faculty of Medicine and Health, The University of Sydney 3 , ,","place":["Sydney, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-5509","authenticated-orcid":true,"given":"Martyn","family":"Bullock","sequence":"additional","affiliation":[{"name":"Cancer Genetics Laboratory, Kolling Institute, The University of Sydney 2 , ,","place":["Sydney, Australia"]},{"name":"Northern Clinical School, Faculty of Medicine and Health, The University of Sydney 3 , ,","place":["Sydney, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Gild","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Royal North Shore Hospital 1 , ,","place":["Sydney, Australia"]},{"name":"Cancer Genetics Laboratory, Kolling Institute, The University of Sydney 2 , ,","place":["Sydney, Australia"]},{"name":"Northern Clinical School, Faculty of Medicine and Health, The University of Sydney 3 , ,","place":["Sydney, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2026070905413450700_bib1","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/0008-5472.CAN-06-4605","article-title":"The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells","volume":"67","author":"Akeno-Stuart","year":"2007","journal-title":"Cancer Res"},{"key":"2026070905413450700_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/ERC-20-0436","article-title":"Targeting EML4-ALK gene fusion variant 3 in thyroid cancer","volume":"28","author":"Aydemirli","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"2026070905413450700_bib3","doi-asserted-by":"crossref","first-page":"viii33","DOI":"10.1093\/annonc\/mdy269.103","article-title":"Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292","volume":"29","author":"Besse","year":"2018","journal-title":"Ann Oncol"},{"key":"2026070905413450700_bib5","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1089\/thy.2019.0514","article-title":"Acquired secondary RAS mutation in BRAF(V600e)-mutated thyroid cancer patients treated with BRAF inhibitors","volume":"30","author":"Cabanillas","year":"2020","journal-title":"Thyroid"},{"key":"2026070905413450700_bib6","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1200\/JCO.2017.73.0226","article-title":"Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II international thyroid oncology group trial","volume":"35","author":"Cabanillas","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026070905413450700_bib7","doi-asserted-by":"crossref","first-page":"e3420","DOI":"10.1210\/clinem\/dgac222","article-title":"Pre- and post-operative circulating tumoral DNA in patients with medullary thyroid carcinoma","volume":"107","author":"Ciampi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905413450700_bib8","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/hed.25155","article-title":"Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma","volume":"40","author":"Condello","year":"2018","journal-title":"Head Neck"},{"key":"2026070905413450700_bib9","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2017-01039","article-title":"Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid carcinoma","volume":"102","author":"Cote","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905413450700_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1530\/EJE-07-0566","article-title":"Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking","volume":"157","author":"D\u2019herbomez","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2026070905413450700_bib11","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"key":"2026070905413450700_bib12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"2026070905413450700_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41574-020-00465-y","article-title":"Multikinase inhibitors in thyroid cancer: timing of targeted therapy","volume":"17","author":"Gild","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2026070905413450700_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2026070905413450700_bib15","first-page":"1","article-title":"Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers","volume":"22","author":"Hong","year":"2024","journal-title":"Clin Adv Hematol Oncol"},{"key":"2026070905413450700_bib16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ejca.2020.11.025","article-title":"Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis","volume":"144","author":"Jones","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026070905413450700_bib17","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1038\/onc.2017.281","article-title":"CUT-PCR: CRISPR-mediated, ultrasensitive detection of target DNA using PCR","volume":"36","author":"Lee","year":"2017","journal-title":"Oncogene"},{"key":"2026070905413450700_bib18","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4065\/mcp.2010.0260","article-title":"Radiation risk from medical imaging","volume":"85","author":"Lin","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"2026070905413450700_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"key":"2026070905413450700_bib20","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1158\/2159-8290.CD-21-1252","article-title":"The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer","volume":"13","author":"Mattox","year":"2023","journal-title":"Cancer Discov"},{"key":"2026070905413450700_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/1097-0142(1984)54:4<657::AID-CNCR2820540412>3.0.CO;2-V","article-title":"Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease","volume":"54","author":"Mendelsohn","year":"1984","journal-title":"Cancer"},{"key":"2026070905413450700_bib22","doi-asserted-by":"crossref","first-page":"R235","DOI":"10.1530\/ERC-15-0070","article-title":"RAS proto-oncogene in medullary thyroid carcinoma","volume":"22","author":"Moura","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"2026070905413450700_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2026070905413450700_bib24","doi-asserted-by":"crossref","first-page":"13379","DOI":"10.1038\/s41598-018-30780-4","article-title":"The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis","volume":"8","author":"Passiglia","year":"2018","journal-title":"Sci Rep"},{"key":"2026070905413450700_bib25","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1089\/thy.2020.0296","article-title":"Clinical utility of circulating cell-free DNA mutations in anaplastic thyroid carcinoma","volume":"31","author":"Qin","year":"2021","journal-title":"Thyroid"},{"key":"2026070905413450700_bib26","doi-asserted-by":"crossref","first-page":"e20210390","DOI":"10.1084\/jem.20210390","article-title":"Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET\u2013rearranged thyroid cancer","volume":"219","author":"Raman","year":"2022","journal-title":"J Exp Med"},{"key":"2026070905413450700_bib27","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1210\/jc.2015-3989","article-title":"Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer","volume":"101","author":"Robinson","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905413450700_bib28","doi-asserted-by":"crossref","first-page":"103207","DOI":"10.18632\/oncotarget.21732","article-title":"PIK3CA(H1047R)-induced paradoxical ERK activation results in resistance to BRAF(V600E) specific inhibitors in BRAF(V600E) PIK3CA(H1047R) double mutant thyroid tumors","volume":"8","author":"Roelli","year":"2017","journal-title":"Oncotarget"},{"key":"2026070905413450700_bib29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070905413450700_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","article-title":"Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin","volume":"164","author":"Snyder","year":"2016","journal-title":"Cell"},{"key":"2026070905413450700_bib31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2026070905413450700_bib32","first-page":"e146","article-title":"Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment","volume":"44","author":"Song","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2026070905413450700_bib33","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1210\/jc.2011-1740","article-title":"Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC)","volume":"96","author":"Spencer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905413450700_bib34","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1210\/en.2004-1134","article-title":"Fibroblast growth factor receptors as molecular targets in thyroid carcinoma","volume":"146","author":"St Bernard","year":"2005","journal-title":"Endocrinology"},{"key":"2026070905413450700_bib35","doi-asserted-by":"crossref","first-page":"13624","DOI":"10.1038\/s41598-021-93084-0","article-title":"Identification of germline cancer predisposition variants during clinical ctDNA testing","volume":"11","author":"Stout","year":"2021","journal-title":"Sci Rep"},{"key":"2026070905413450700_bib36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1590\/S1807-59322009000700015","article-title":"Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma","volume":"64","author":"Toledo","year":"2009","journal-title":"Clinics"},{"key":"2026070905413450700_bib37","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"2026070905413450700_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/thy.2021.0680","article-title":"A case report of poor response to selpercatinib in the presence of a 632_633 RET deletion","volume":"33","author":"Wijewardene","year":"2023","journal-title":"Thyroid"},{"key":"2026070905413450700_bib39","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.3390\/cancers13143443","article-title":"Translational utility of liquid biopsies in thyroid cancer management","volume":"13","author":"Wijewardene","year":"2021","journal-title":"Cancers"},{"key":"2026070905413450700_bib40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070905413450700_bib41","doi-asserted-by":"crossref","first-page":"e230002","DOI":"10.1530\/ERC-23-0002","article-title":"Liquid biopsies in thyroid cancers: a systematic review and meta-analysis","volume":"30","author":"Zeyghami","year":"2023","journal-title":"Endocrine-Related Cancer"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/2\/ERC-24-0227.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/2\/ERC-24-0227.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0227\/144808\/erc-24-0227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0227\/144808\/erc-24-0227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:41:44Z","timestamp":1783590104000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/2\/e240227\/25883\/Evaluating-the-prognostic-potential-of-circulating"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0227","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"article-number":"e240227"}}